{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["SARS-CoV2", "homology modelling", "in silico", "membrane glycoprotein", "molecular dynamics", "phyto-compound"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": [], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "35462888", "DateRevised": {"Year": "2022", "Month": "07", "Day": "16"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "04", "Day": "07"}], "Language": ["eng"], "ELocationID": ["805344", "10.3389/fphar.2022.805344"], "Journal": {"ISSN": "1663-9812", "JournalIssue": {"Volume": "13", "PubDate": {"Year": "2022"}}, "Title": "Frontiers in pharmacology", "ISOAbbreviation": "Front Pharmacol"}, "ArticleTitle": "Plant Source Derived Compound Exhibited <i>In Silico</i> Inhibition of Membrane Glycoprotein In SARS-CoV-2: Paving the Way to Discover a New Class of Compound For Treatment of COVID-19.", "Pagination": {"StartPage": "805344", "MedlinePgn": "805344"}, "Abstract": {"AbstractText": ["SARS-CoV-2 is the virus responsible for causing COVID-19 disease in humans, creating the recent pandemic across the world, where lower production of Type I Interferon (IFN-I) is associated with the deadly form of the disease. Membrane protein or SARS-CoV-2 M proteins are known to be the major reason behind the lower production of human IFN-I by suppressing the expression of IFN\u03b2 and Interferon Stimulated Genes. In this study, 7,832 compounds from 32 medicinal plants of India possessing traditional knowledge linkage with pneumonia-like disease treatment, were screened against the Homology-Modelled structure of SARS-CoV-2 M protein with the objective of identifying some active phytochemicals as inhibitors. The entire study was carried out using different modules of Schrodinger Suite 2020-3. During the docking of the phytochemicals against the SARS-CoV-2 M protein, a compound, ZIN1722 from <i>Zingiber officinale</i> showed the best binding affinity with the receptor with a Glide Docking Score of -5.752 and Glide gscore of -5.789. In order to study the binding stability, the complex between the SARS-CoV-2 M protein and ZIN1722 was subjected to 50\u00a0ns Molecular Dynamics simulation using Desmond module of Schrodinger suite 2020-3, during which the receptor-ligand complex showed substantial stability after 32\u00a0ns of MD Simulation. The molecule ZIN1722 also showed promising results during ADME-Tox analysis performed using Swiss ADME and pkCSM. With all the findings of this extensive computational study, the compound ZIN1722 is proposed as a potential inhibitor to the SARS-CoV-2 M protein, which may subsequently prevent the immunosuppression mechanism in the human body during the SARS-CoV-2 virus infection. Further studies based on this work would pave the way towards the identification of an effective therapeutic regime for the treatment and management of SARS-CoV-2 infection in a precise and sustainable manner."], "CopyrightInformation": "Copyright \u00a9 2022 Mahanta, Naiya, Biswas, Changkakoti, Mohanta, Tanti, Mishra, Mohanta and Sharma."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "National Institute of Electronics and Information Technology (NIELIT), Guwahati, India."}], "LastName": "Mahanta", "ForeName": "Saurov", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biotechnology, Maulana Abul Kalam Azad University of Technology, West Bengal, India."}], "LastName": "Naiya", "ForeName": "Tufan", "Initials": "T"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Centre for Nanoscience and Nanotechnology, Sathyabama Institute of Science and Technology, Chennai, India."}], "LastName": "Biswas", "ForeName": "Kunal", "Initials": "K"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "National Institute of Electronics and Information Technology (NIELIT), Guwahati, India."}], "LastName": "Changkakoti", "ForeName": "Liza", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Applied Biology, School of Biological Sciences, University of Science and Technology Meghalaya (USTM), Baridua, India."}], "LastName": "Mohanta", "ForeName": "Yugal Kishore", "Initials": "YK"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Botany, Gauhati University, Guwahati, India."}], "LastName": "Tanti", "ForeName": "Bhaben", "Initials": "B"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biotechnology, Yeungnam University, Gyeongsan, South Korea."}], "LastName": "Mishra", "ForeName": "Awdhesh Kumar", "Initials": "AK"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Natural and Medical Sciences Research Centre, University of Nizwa, Nizwa, Oman."}], "LastName": "Mohanta", "ForeName": "Tapan Kumar", "Initials": "TK"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Bioresources and Sustainable Development, Imphal, India."}], "LastName": "Sharma", "ForeName": "Nanaocha", "Initials": "N"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Front Pharmacol", "NlmUniqueID": "101548923", "ISSNLinking": "1663-9812"}, "CoiStatement": "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Al-Sehemi A. G., Pannipara M., Parulekar R. S., Patil O., Choudhari P. B., Bhatia M. S., et al. (2020). Potential of NO Donor Furoxan as SARS-CoV-2 Main Protease (Mpro) Inhibitors: In Silico Analysis. J. Biomol. Struct. Dyn. 1, 1\u201315. 10.1080/07391102.2020.1790038", "ArticleIdList": ["10.1080/07391102.2020.1790038", "PMC7441807", "32643550"]}, {"Citation": "Al-Sehemi A. G., Parulekar R. S., Pannipara M., Manzur Ali P P, Zubaidha P. K., Bhatia M. S., et al. (2021). In Silico evaluation of NO Donor Heterocyclic Vasodilators as SARS-CoV-2 Mpro Protein Inhibitor. J. Biomol. Struct. Dyn. 1, 1\u201318. 10.1080/07391102.2021.2005682", "ArticleIdList": ["10.1080/07391102.2021.2005682", "34809523"]}, {"Citation": "Andrianov A. M., Kornoushenko Y. V., Karpenko A. D., Bosko I. P., Tuzikov A. V. (2020). Computational Discovery of Small Drug-like Compounds as Potential Inhibitors of SARS-CoV-2 Main Protease. J. Biomol. Struct. Dyn. 39, 1\u201313. 10.1080/07391102.2020.1792989", "ArticleIdList": ["10.1080/07391102.2020.1792989", "PMC7441783", "32662333"]}, {"Citation": "Aouidate A., Ghaleb A., Chtita S., Aarjane M., Ousaa A., Maghat H., et al. (2021). Identification of a Novel Dual-Target Scaffold for 3CLpro and RdRp Proteins of SARS-CoV-2 Using 3D-Similarity Search, Molecular Docking, Molecular Dynamics and ADMET Evaluation. J. Biomol. Struct. Dyn. 39, 4522\u20134535. 10.1080/07391102.2020.1779130", "ArticleIdList": ["10.1080/07391102.2020.1779130", "PMC7309310", "32552534"]}, {"Citation": "Bhowmik D., Nandi R., Jagadeesan R., Kumar N., Prakash A., Kumar D. (2020). Identification of Potential Inhibitors against SARS-CoV-2 by Targeting Proteins Responsible for Envelope Formation and Virion Assembly Using Docking Based Virtual Screening, and Pharmacokinetics Approaches. Infect. Genet. Evol. 84, 104451. 10.1016/j.meegid.2020.104451", "ArticleIdList": ["10.1016/j.meegid.2020.104451", "PMC7335633", "32640381"]}, {"Citation": "Bianchi M., Benvenuto D., Giovanetti M., Angeletti S., Ciccozzi M., Pascarella S. (2020). \u201cSars-CoV-2 Envelope and Membrane Proteins: Differences from Closely Related Proteins Linked to Cross-Species Transmission?,\u201d in Molecular Surveillance of Emerging Pathogens Using Bioinformatic and Bayesian Phylogeny View Project. 10.20944/preprints202004.0089.v1", "ArticleIdList": ["10.20944/preprints202004.0089.v1"]}, {"Citation": "Boeckmann B., Bairoch A., Apweiler R., Blatter M. C., Estreicher A., Gasteiger E., et al. (2003). The SWISS-PROT Protein Knowledgebase and its Supplement TrEMBL in 2003. Nucleic Acids Res. 31, 365\u2013370. 10.1093/nar/gkg095", "ArticleIdList": ["10.1093/nar/gkg095", "PMC165542", "12520024"]}, {"Citation": "Daina A., Michielin O., Zoete V. (2017). SwissADME: A Free Web Tool to Evaluate Pharmacokinetics, Drug-Likeness and Medicinal Chemistry Friendliness of Small Molecules. Sci. Rep. 7, 42717. 10.1038/srep42717", "ArticleIdList": ["10.1038/srep42717", "PMC5335600", "28256516"]}, {"Citation": "Das S. K., Mahanta S., Tanti B., Tag H., Hui P. K. (2021). Identification of Phytocompounds from Houttuynia Cordata Thunb. As Potential Inhibitors for SARS-CoV-2 Replication Proteins through GC-MS/LC-MS Characterization, Molecular Docking and Molecular Dynamics Simulation. Mol. Divers. 26, 365\u2013388. 10.1007/s11030-021-10226-2", "ArticleIdList": ["10.1007/s11030-021-10226-2", "PMC8103070", "33961167"]}, {"Citation": "Elekofehinti O. O., Iwaloye O., Josiah S. S., Lawal A. O., Akinjiyan M. O., Ariyo E. O. (2021). Molecular Docking Studies, Molecular Dynamics and ADME/tox Reveal Therapeutic Potentials of STOCK1N-69160 against Papain-like Protease of SARS-CoV-2. Mol. Divers. 25, 1761\u20131773. 10.1007/s11030-020-10151-w", "ArticleIdList": ["10.1007/s11030-020-10151-w", "PMC7670485", "33201386"]}, {"Citation": "Elfiky A. A. (2021). SARS-CoV-2 RNA Dependent RNA Polymerase (RdRp) Targeting: an In Silico Perspective. J. Biomol. Struct. Dyn. 39, 3204\u20133212. 10.1080/07391102.2020.1761882", "ArticleIdList": ["10.1080/07391102.2020.1761882", "PMC7222627", "32338164"]}, {"Citation": "Fu Y. Z., Wang S. Y., Zheng Z. Q., Yi Huang Yi., Li W. W., Xu Z. S., et al. (2021). SARS-CoV-2 Membrane Glycoprotein M Antagonizes the MAVS-Mediated Innate Antiviral Response. Cell Mol Immunol 18, 613\u2013620. 10.1038/s41423-020-00571-x", "ArticleIdList": ["10.1038/s41423-020-00571-x", "PMC7588591", "33110251"]}, {"Citation": "Gentile D., Patamia V., Scala A., Sciortino M. T., Piperno A., Rescifina A. (2020). Putative Inhibitors of SARS-COV-2 Main Protease from a Library of marine Natural Products: A Virtual Screening and Molecular Modeling Study. Mar. Drugs 18, 225. 10.3390/md18040225", "ArticleIdList": ["10.3390/md18040225", "PMC7231030", "32340389"]}, {"Citation": "Gimeno A., Mestres-Truyol J., Ojeda-Montes M. J., Macip G., Saldivar-Espinoza B., Cereto-Massagu\u00e9 A., et al. (2020). Prediction of Novel Inhibitors of the Main Protease (M-Pro) of SARS-CoV-2 through Consensus Docking and Drug Reposition. Int. J. Mol. Sci. 21, 3793. 10.3390/ijms21113793", "ArticleIdList": ["10.3390/ijms21113793", "PMC7312484", "32471205"]}, {"Citation": "Gogoi M., Borkotoky M., Borchetia S., Chowdhury P., Mahanta S., Barooah A. K. (2021). Black tea Bioactives as Inhibitors of Multiple Targets of SARS-CoV-2 (3CLpro, PLpro and RdRp): a Virtual Screening and Molecular Dynamic Simulation Study. J. Biomol. Struct. Dyn., 1\u201324. 10.1080/07391102.2021.1897679", "ArticleIdList": ["10.1080/07391102.2021.1897679", "33715595"]}, {"Citation": "Ho B. K., Thomas A., Brasseur R. (2009). Revisiting the Ramachandran Plot: Hard-Sphere Repulsion, Electrostatics, and H-Bonding in the Alpha-helix. Protein Sci. 12, 2508\u20132522. 10.1110/ps.03235203", "ArticleIdList": ["10.1110/ps.03235203", "PMC2366959", "14573863"]}, {"Citation": "Ita K. (2021). Coronavirus Disease (COVID-19): Current Status and Prospects for Drug and Vaccine Development. Arch. Med. Res. 52, 15\u201324. 10.1016/j.arcmed.2020.09.010", "ArticleIdList": ["10.1016/j.arcmed.2020.09.010", "PMC7832760", "32950264"]}, {"Citation": "Jayaram B., Dhingra P., Mishra A., Kaushik R., Mukherjee G., Singh A., et al. (2014). Bhageerath-H: A Homology/Ab Initio Hybrid Server for Predicting Tertiary Structures of Monomeric Soluble Proteins. BMC Bioinformatics 15, S7. 10.1186/1471-2105-15-S16-S7", "ArticleIdList": ["10.1186/1471-2105-15-S16-S7", "PMC4290660", "25521245"]}, {"Citation": "Jim\u00e9nez-Alberto A., Ribas-Aparicio R. M., Aparicio-Ozores G., Castel\u00e1n-Vega J. A. (2020). Virtual Screening of Approved Drugs as Potential SARS-CoV-2 Main Protease Inhibitors. Comput. Biol. Chem. 88, 107325. 10.1016/j.compbiolchem.2020.107325", "ArticleIdList": ["10.1016/j.compbiolchem.2020.107325", "PMC7316061", "32623357"]}, {"Citation": "Khan A., Khan M., Saleem S., Babar Z., Ali A., Khan A. A., et al. (2020). Phylogenetic Analysis and Structural Perspectives of RNA-dependent RNA-Polymerase Inhibition from SARs-CoV-2 with Natural Products. Interdiscip. Sci. 12, 335\u2013348. 10.1007/s12539-020-00381-9", "ArticleIdList": ["10.1007/s12539-020-00381-9", "PMC7332347", "32617855"]}, {"Citation": "Kim S., Chen J., Cheng T., Gindulyte A., He J., He S., et al. (2021). PubChem in 2021: New Data Content and Improved Web Interfaces. Nucleic Acids Res. 49, D1388\u2013D1395. 10.1093/nar/gkaa971", "ArticleIdList": ["10.1093/nar/gkaa971", "PMC7778930", "33151290"]}, {"Citation": "Lipinski C. A. (2004). Lead- and Drug-like Compounds: The Rule-Of-Five Revolution. Drug Discov. Today Technol. 1, 337\u2013341. 10.1016/j.ddtec.2004.11.007", "ArticleIdList": ["10.1016/j.ddtec.2004.11.007", "24981612"]}, {"Citation": "Mohanta T. K. (2020). Corona Virus (CoVid19) Genome: Genomic and Biochemical Analysis Revealed its Possible Synthetic Origin. J. Appl. Biotechnol. Bioeng. 7, 200\u2013213. 10.15406/jabb.2020.07.00235", "ArticleIdList": ["10.15406/jabb.2020.07.00235"]}, {"Citation": "Mohanta T. K., Sharma N., Arina P., Defilippi P. (2020a). Molecular Insights into the MAPK Cascade during Viral Infection: Potential Crosstalk between HCQ and HCQ Analogues. Biomed. Res. Int. 2020, 1\u20139. 10.1155/2020/8827752", "ArticleIdList": ["10.1155/2020/8827752", "PMC7780227", "33426074"]}, {"Citation": "Mohanta T. K., Sharma N., Arina P., Defilippi P. (2020b). Molecular Insights into the MAPK Cascade during Viral Infection: Potential Crosstalk between HCQ and HCQ Analogues. Biomed. Res. Int. 2020, 8827752\u20138827759. 10.1155/2020/8827752", "ArticleIdList": ["10.1155/2020/8827752", "PMC7780227", "33426074"]}, {"Citation": "Morgon N. H., Grandini G. S., Yoguim M. I., Porto C. M., Santana L. C., Biswas S., et al. (2021). Potential Activity of Linezolid against SARS-CoV-2 Using Electronic and Molecular Docking Study. J. Mol. Model. 27, 222. 10.1007/s00894-021-04828-8", "ArticleIdList": ["10.1007/s00894-021-04828-8", "PMC8264178", "34236527"]}, {"Citation": "Naik B., Gupta N., Ojha R., Singh S., Prajapati V. K., Prusty D. (2020). High Throughput Virtual Screening Reveals SARS-CoV-2 Multi-Target Binding Natural Compounds to lead Instant Therapy for COVID-19 Treatment. Int. J. Biol. Macromol 160, 1\u201317. 10.1016/j.ijbiomac.2020.05.184", "ArticleIdList": ["10.1016/j.ijbiomac.2020.05.184", "PMC7250083", "32470577"]}, {"Citation": "Nand M., Maiti P., Joshi T., Chandra S., Pande V., Kuniyal J. C., et al. (2020). Virtual Screening of Anti-HIV1 Compounds against SARS-CoV-2: Machine Learning Modeling, Chemoinformatics and Molecular Dynamics Simulation Based Analysis. Sci. Rep. 10, 20397. 10.1038/s41598-020-77524-x", "ArticleIdList": ["10.1038/s41598-020-77524-x", "PMC7683650", "33230180"]}, {"Citation": "\nPadma T. V. (2021). COVID Vaccines to Reach Poorest Countries in 2023 - Despite Recent Pledges. Nature\n595, 342\u2013343. 10.1038/d41586-021-01762-w\nAvailable from: https://www.nature.com/articles/d41586-021-01762-w (Accessed October 24, 2021)\n", "ArticleIdList": ["10.1038/d41586-021-01762-w", "34226742"]}, {"Citation": "Palmeira A., Sousa E., K\u00f6seler A., Sabirli R., G\u00f6ren T., T\u00fcrk\u00e7\u00fcer \u0130., et al. (2020). Preliminary Virtual Screening Studies to Identify Grp78 Inhibitors Which May Interfere with Sars-Cov-2 Infection. Pharmaceuticals (Basel) 13, 1\u201313. 10.3390/ph13060132", "ArticleIdList": ["10.3390/ph13060132", "PMC7345920", "32630514"]}, {"Citation": "Paul D., Mahanta S., Tag H., Das S. K., das Gupta D., Tanti B., et al. (2021). Identification of Tyrosine Kinase Inhibitors from Panax Bipinnatifidus and Panax Pseudoginseng for RTK-HER2 and VEGFR2 Receptors, by In Silico Approach. Mol. Divers. 10.1007/s11030-021-10304-5", "ArticleIdList": ["10.1007/s11030-021-10304-5", "34554395"]}, {"Citation": "Peacock T. P., Goldhill D. H., Zhou J., Baillon L., Frise R., Swann O. C., et al. (2021). The Furin Cleavage Site in the SARS-CoV-2 Spike Protein Is Required for Transmission in Ferrets. Nat. Microbiol. 6, 899\u2013909. 10.1038/s41564-021-00908-w", "ArticleIdList": ["10.1038/s41564-021-00908-w", "33907312"]}, {"Citation": "Pires D. E., Blundell T. L., Ascher D. B. (2015). pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures. J. Med. Chem. 58, 4066\u20134072. 10.1021/acs.jmedchem.5b00104", "ArticleIdList": ["10.1021/acs.jmedchem.5b00104", "PMC4434528", "25860834"]}, {"Citation": "Puttaswamy H., Gowtham H. G., Ojha M. D., Yadav A., Choudhir G., Raguraman V., et al. (2020). In Silico studies Evidenced the Role of Structurally Diverse Plant Secondary Metabolites in Reducing SARS-CoV-2 Pathogenesis. Sci. Rep. 10, 20584. 10.1038/s41598-020-77602-0", "ArticleIdList": ["10.1038/s41598-020-77602-0", "PMC7689506", "33239694"]}, {"Citation": "Roman Laskowski B. A., Macarthur M. W., Thornton J. M. (1983). Computer Programs PROCHECK: A Program to Check the Stereochemicai Quality of Protein Structures."}, {"Citation": "Saxena A. (2020). Drug Targets for COVID-19 Therapeutics: Ongoing Global Efforts. J. Biosci. 45, 87. 10.1007/s12038-020-00067-w", "ArticleIdList": ["10.1007/s12038-020-00067-w", "PMC7323606", "32661214"]}, {"Citation": "Schreiber G. (2020). The Role of Type I Interferons in the Pathogenesis and Treatment of COVID-19. Front. Immunol. 11, 595739. 10.3389/fimmu.2020.595739", "ArticleIdList": ["10.3389/fimmu.2020.595739", "PMC7561359", "33117408"]}, {"Citation": "Schr\u00f6dinger L. L. C. (2017). Schr\u00f6dinger Suite (New York, NY: Schr\u00f6dinger, LLC; ), 2, 2011\u20132017."}, {"Citation": "Semwal D. K., Semwal R. B., Combrinck S., Viljoen A. (2016). Myricetin: A Dietary Molecule with Diverse Biological Activities. Nutrients 8, 90. 10.3390/nu8020090", "ArticleIdList": ["10.3390/nu8020090", "PMC4772053", "26891321"]}, {"Citation": "Shamsi A., Mohammad T., Anwar S., AlAjmi M. F., Hussain A., Rehman M. T., et al. (2020). Glecaprevir and Maraviroc Are High-Affinity Inhibitors of SARS-CoV-2 Main Protease: Possible Implication in COVID-19 Therapy. Biosci. Rep. 40, BSR20201256. 10.1042/BSR20201256", "ArticleIdList": ["10.1042/BSR20201256", "PMC7268261", "32441299"]}, {"Citation": "Singh T., Biswas D., Jayaram B. (2011). AADS--an Automated Active Site Identification, Docking, and Scoring Protocol for Protein Targets Based on Physicochemical Descriptors. J. Chem. Inf. Model. 51, 2515\u20132527. 10.1021/ci200193z", "ArticleIdList": ["10.1021/ci200193z", "21877713"]}, {"Citation": "Song X., Tan L., Wang M., Ren C., Guo C., Yang B., et al. (2021). Myricetin: A Review of the Most Recent Research. Biomed. Pharmacother. 134, 111017. 10.1016/j.biopha.2020.111017", "ArticleIdList": ["10.1016/j.biopha.2020.111017", "33338751"]}, {"Citation": "Sridhar S., Saha G., Lata S., Mehrotra R. (2021). Molecular Docking Studies of Indian Variants of Pathophysiological Proteins of SARS-CoV-2 with Selected Drug Candidates. J. Genet. 100, 64. 10.1007/s12041-021-01313-2", "ArticleIdList": ["10.1007/s12041-021-01313-2", "PMC8435403", "34553696"]}, {"Citation": "\nSuganya R., Kalva S., Saleena L. M., Rathi Suganya P., Sudevan K. (2014). Homology Modeling for Human ADAM12 Using Prime, I-Tasser and Easymodeller Molecular Modelling of Synthetic Ion Channels View Project Structure Based Pharmacophore Modelling and Docking with Adam 33 for Identification of Natural lead Compounds View Project HOMOLOGY MODELING for HUMAN ADAM12 USING PRIME, I-TASSER and EASYMODELLER. Available from: https://www.researchgate.net/publication/286503309\n. "}, {"Citation": "Tatar G., Ozyurt E., Turhan K. (2021). Computational Drug Repurposing Study of the RNA Binding Domain of SARS-CoV-2 Nucleocapsid Protein with Antiviral Agents. Biotechnol. Prog. 37, e3110. 10.1002/btpr.3110", "ArticleIdList": ["10.1002/btpr.3110", "PMC7883068", "33314794"]}, {"Citation": "Tay M. Z., Poh C. M., R\u00e9nia L., MacAry P. A., Ng L. F. P. (2020). The trinity of COVID-19: Immunity, Inflammation and Intervention. Nat. Rev. Immunol. 20, 363\u2013374. 10.1038/s41577-020-0311-8", "ArticleIdList": ["10.1038/s41577-020-0311-8", "PMC7187672", "32346093"]}, {"Citation": "Tazikeh-Lemeski E., Moradi S., Raoufi R., Shahlaei M., Janlou M. A. M., Zolghadri S. (2021). Targeting SARS-COV-2 Non-structural Protein 16: a Virtual Drug Repurposing Study. J. Biomol. Struct. Dyn. 39, 4633\u20134646. 10.1080/07391102.2020.1779133", "ArticleIdList": ["10.1080/07391102.2020.1779133", "PMC7332864", "32573355"]}, {"Citation": "Thuy B. T. P., My T. T. A., Hai N. T. T., Hieu L. T., Hoa T. T., Thi Phuong Loan H., et al. (2020). Investigation into SARS-CoV-2 Resistance of Compounds in Garlic Essential Oil. ACS Omega 5, 8312\u20138320. 10.1021/acsomega.0c00772", "ArticleIdList": ["10.1021/acsomega.0c00772", "PMC7123907", "32363255"]}, {"Citation": "Venselaar H., Joosten R. P., Vroling B., Baakman C. A., Hekkelman M. L., Krieger E., et al. (2010). Homology Modelling and Spectroscopy, a Never-Ending Love story. Eur. Biophys. J. 39, 551\u2013563. 10.1007/s00249-009-0531-0", "ArticleIdList": ["10.1007/s00249-009-0531-0", "PMC2841279", "19718498"]}, {"Citation": "\nWHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard with Vaccination Data\nAvailable from: https://covid19.who.int/\n (Accessed October 22, 2021). "}, {"Citation": "Wiederstein M., Sippl M. J. (2007). ProSA-web: Interactive Web Service for the Recognition of Errors in Three-Dimensional Structures of Proteins. Nucleic Acids Res. 35, W407\u2013W410. 10.1093/nar/gkm290", "ArticleIdList": ["10.1093/nar/gkm290", "PMC1933241", "17517781"]}, {"Citation": "Wilmes G. M., Archambault V., Austin R. J., Jacobson M. D., Bell S. P., Cross F. R. (2004). Interaction of the S-phase Cyclin Clb5 with an \"RXL\" Docking Sequence in the Initiator Protein Orc6 Provides an Origin-Localized Replication Control Switch. Genes Dev. 18, 981\u2013991. 10.1101/gad.1202304", "ArticleIdList": ["10.1101/gad.1202304", "PMC406289", "15105375"]}, {"Citation": "Wu C., Liu Y., Yang Y., Zhang P., Zhong W., Wang Y., et al. (2020). Analysis of Therapeutic Targets for SARS-CoV-2 and Discovery of Potential Drugs by Computational Methods. Acta Pharm. Sin B 10, 766\u2013788. 10.1016/j.apsb.2020.02.008", "ArticleIdList": ["10.1016/j.apsb.2020.02.008", "PMC7102550", "32292689"]}, {"Citation": "Yu M. S., Lee J., Lee J. M., Kim Y., Chin Y. W., Jee J. G., et al. (2012). Identification of Myricetin and Scutellarein as Novel Chemical Inhibitors of the SARS Coronavirus Helicase, nsP13. Bioorg. Med. Chem. Lett. 22, 4049\u20134054. 10.1016/j.bmcl.2012.04.081", "ArticleIdList": ["10.1016/j.bmcl.2012.04.081", "PMC7127438", "22578462"]}, {"Citation": "Zheng Y., Zhuang L., Han M. L., Kang D., Gaou C., Wang P. H., et al. (2020). Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Membrane (M) Protein Inhibits Type I and III Interferon Production by Targeting RIG-I/MDA-5 Signaling. Signal. Transduct Target. Thery 5, 299. 10.1038/s41392-020-00438-7", "ArticleIdList": ["10.1038/s41392-020-00438-7", "PMC7768267", "33372174"]}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "11", "Day": "1"}, {"Year": "2022", "Month": "3", "Day": "4"}, {"Year": "2022", "Month": "4", "Day": "25", "Hour": "5", "Minute": "13"}, {"Year": "2022", "Month": "4", "Day": "26", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "4", "Day": "26", "Hour": "6", "Minute": "1"}, {"Year": "2022", "Month": "4", "Day": "7"}], "PublicationStatus": "epublish", "ArticleIdList": ["35462888", "PMC9022603", "10.3389/fphar.2022.805344", "805344"]}}], "PubmedBookArticle": []}